GERN
Geron Corporation
$1.54
+$0.17(+12.41%)
54
Overall
60
Value
66
Tech
36
Quality
Market Cap
$695.81M
Volume
27.15M
52W Range
$1.04 - $3.09
Target Price
$3.17
Company Overview
| Mkt Cap | $695.81M | Price | $1.54 |
| Volume | 27.15M | Change | +12.41% |
| P/E Ratio | -4.0 | Open | $1.35 |
| Revenue | $77.0M | Prev Close | $1.37 |
| Net Income | $-174.6M | 52W Range | $1.04 - $3.09 |
| Div Yield | N/A | Target | $3.17 |
| Overall | 54 | Value | 60 |
| Quality | 36 | Technical | 66 |
No chart data available
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.
Sector: Healthcare
Industry: Biotechnology
Latest News
Geron Issues 2026 Guidance Emphasizing RYTELO Growth
TipRanks Auto-Generated Newsdesk•22 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GERN | $1.54 | +12.4% | 27.15M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |